Reveal Pharmaceuticals Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Reveal is a clinical-stage biotechnology company developing a next-generation MRI contrast agent currently in Phase 2 clinical trials with FDA Fast Track designation. Our mission is to transform contrast-enhanced MRI and address three major challenges: patient safety, environmental impact, and healthcare supply-chain resilience.

More than 60 million MRI scans with contrast are performed each year. Current contrast  agents rely on the heavy metal gadolinium, which accumulates in patients, contributes to rising levels of gadolinium in surface waters, and depends on a vulnerable rare-earth supply chain.

Reveal’s patented gadolinium-free contrast agents use manganese, an element that is abundant in nature and essential for human biology. Our work has been awarded over $15 million in NIH SBIR grant funding, reflecting strong validation of our technology and its potential impact. Our investors include patients, physicians, and industry experts who share our commitment to advancing safer and more sustainable medical imaging.

Sign up for free to view info

Company overview Employee directory